Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bivalent Norovirus vaccine - Vaxart

Drug Profile

Bivalent Norovirus vaccine - Vaxart

Alternative Names: Bivalent GII.4 vaccine - Vaxart; GI.1 oral vaccine tablet + GII.4 oral vaccine tablet; Norovirus GI.1 vaccine + Norovirus GII.4 vaccine; VXA-G1.1-NN + VXA-G2.4-NS

Latest Information Update: 14 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaxart
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Norovirus infections

Most Recent Events

  • 02 Oct 2019 Immunogenicity data from a clinical trial in Norovirus infections presented at the IDWeek (IDW-2019)
  • 01 Oct 2019 Vaxart completes a phase Ib trial for Norovirus infections (Prevention) in USA before October 2019 (NCT03897309) (Vaxart pipeline, October 2019)
  • 25 Sep 2019 Adverse events and immunogenicity data from a phase Ib trial in Norovirus infections released by Vaxart
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top